For those interested in radioligand therapy against FAP antigen expressing cancer, Ratio Therapeutics is recruiting for a Phase 1/2 Open-label Study (NCT07156565).
Eligibility requires history of relapse and refractory soft tissue sarcoma. Recruiting in US and Canada.